Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies

Novel therapies including kinase inhibitors (KI) have led to high and durable response in patients with chronic lymphocytic leukemia (CLL), however, some patients stop therapy. This study evaluates reasons for treatment changes among CLL patients who stopped KI in real-world practice. Sixty-nine US...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Biol Ther
Autores principales: Mato, Anthony R., Samp, Jennifer C., Gauthier, Geneviève, Terasawa, Emi, Brander, Danielle M.
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2018
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5989798/
https://ncbi.nlm.nih.gov/pubmed/29584544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1449616
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares